Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Accured Expenses (2016 - 2025)

Cardiff Oncology's Change in Accured Expenses history spans 15 years, with the latest figure at $940000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 4.68% year-over-year to $940000.0; the TTM value through Dec 2025 reached $2.2 million, down 26.23%, while the annual FY2025 figure was $2.2 million, 26.23% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $940000.0 at Cardiff Oncology, up from -$2.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.3 million in Q2 2025 and bottomed at -$2.0 million in Q3 2025.
  • The 5-year median for Change in Accured Expenses is $203000.0 (2023), against an average of $411578.9.
  • The largest annual shift saw Change in Accured Expenses soared 2307.46% in 2021 before it crashed 196000.0% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$30000.0 in 2021, then tumbled by 4456.67% to -$1.4 million in 2022, then soared by 202.63% to $1.4 million in 2023, then plummeted by 35.99% to $898000.0 in 2024, then grew by 4.68% to $940000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Change in Accured Expenses are $940000.0 (Q4 2025), -$2.0 million (Q3 2025), and $4.3 million (Q2 2025).